TRAIL-R2 is of particular interest due to our previous report that identified TRAIL-R2 upregulation and TRAIL pathway engagement as mechanisms for the enhanced NK-mediated lysis of PCa cells exposed to another DDR inhibitor, the PARP inhibitor (PARPi) olaparib [16]. The gene discussed is TNFSF10; the disease is posterior cortical atrophy.